SAN FRANCISCO, April 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that positive preclinical and clinical results for its pipeline programs will be presented at numerous medical and scientific meetings over the coming months. These presentations will highlight Nektar's novel therapeutic candidates in the areas of oncology, anti-infectives and central nervous system (CNS), which leverage Nektar's innovative small molecule PEGylation and liquid aerosol platforms.
The data presentations are as follows:
-- April 12-16, 2008: Presentation of Positive Preclinical Data for
NKTR-102 (PEG-irinotecan) at the American Association for Cancer Research
(AACR) Annual Meeting in San Diego, California:
Poster #766: "Enhanced anti-tumor activity of NKTR-102, a novel
PEGylated-irinotecan, when administered in combination with
bevacizumab in a mouse model of human colorectal tumors"
Poster #5741: "NKTR-102, a novel PEGylated-irinotecan, has an
enhanced pharmacokinetic profile with reduced gastrointestinal and
hematopoietic toxicity compared to irinotecan with repeat dosing"
Poster #5742: "NKTR-102, a novel PEGylated-irinotecan, has a
superior acute safety, tolerability, and pharmacokinetic profile
compared to irinotecan"
-- May 8-10, 2008: Presentation of Phase 1 Clinical Trial Multi-Dose
Safety Data for NKTR-118 (oral PEG-naloxol) in Opioid Bowel Dysfunction at
the American Pain Society (APS) Meeting in Tampa, Florida:
Poster #210: "Results from a phase I, double-blind, randomized,
placebo-controlled, multiple-dose study evaluating the safety,
|SOURCE Nektar Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved